Table of Contents
Conference Papers in Medicine
Volume 2013, Article ID 764619, 4 pages
Conference Paper

Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine

Klinik für Innere Medizin-Kardiologie, Schön Klinik Neustadt, Am Kiebitzberg 10, 23730 Neustadt, Germany

Received 24 March 2013; Accepted 14 May 2013

Academic Editors: E. Giannitsis, C. Hamm, M. Möckel, and J. Searle

This Conference Paper is based on a presentation given by Peter W. Radke at “Clinical Decisions in Acute Patients: ACS–POCT–Hypertension and Biomarkers” held from 19 October 2012 to 20 October 2012 in Berlin, Germany.

Copyright © 2013 Peter W. Radke. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Antithrombin and antiplatelet therapies have been in the focus of pharmacological developments over recent years with an increasing number of anticoagulants and antiplatelets becoming available. While these drugs share common pharmacological characteristics (i.e., antiplatelet drugs binding to the P2Y12 receptor), they also differ substantially regarding metabolism, type of receptor binding, clinical end points that have been reduced as compared to the current gold standard, and, consequently, the spectrum of indication. These differences pose the need and, above that, great chances for therapy personalization. Understanding the challenges and opportunities that arise from the use of biological markers in guiding antiplatelet therapy is mandatory to provide best medical practice for patients with acute coronary syndromes.